ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer

BACKGROUND: Broadened use of predictive molecular and phenotypic profiling amongst oncologists has facilitated optimal integration of targeted- and immuno-therapeutics into clinical care. However, the use of predictive immunomarkers in ovarian cancer (OC) has not consistently translated into clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Rocconi, Rodney P., Stanbery, Laura, Tang, Min, Madeira da Silva, Luciana, Walter, Adam, Monk, Bradley J., Herzog, Thomas J., Coleman, Robert L., Manning, Luisa, Wallraven, Gladice, Horvath, Staci, Bognar, Ernest, Senzer, Neil, Brun, Scott, Nemunaitis, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424215/
https://www.ncbi.nlm.nih.gov/pubmed/36051466
http://dx.doi.org/10.1038/s43856-022-00163-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424215/
https://www.ncbi.nlm.nih.gov/pubmed/36051466
http://dx.doi.org/10.1038/s43856-022-00163-y

Ejemplares similares